Affinity Biologicals Overview
- Founded
-
1987

- Status
-
Acquired/Merged
- Employees
-
25

- Latest Deal Type
-
M&A
Affinity Biologicals General Information
Description
Manufacturer of products used worldwide in thrombosis and hemostasis research and medical diagnostics. The company's product line includes an extensive line of antibodies to coagulation and hemostasis-related proteins, conjugates, antibody pairs for immunoassay of human and animal analytes, ELISA (enzyme-linked immunosorbent assay) kits, and a full line of human plasma products including immune-depleted plasmas, calibrators, and controls, along with services such as protein purification, antibody production, assay development, custom manufacturing, and lyophilization.
Contact Information
(Operating Subsidiary)
- 1348 Sandhill Drive
- Ancaster, Ontario L9G 4V5
- Canada
Affinity Biologicals Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
2. Merger/Acquisition | 01-Nov-2018 | 00000 | Completed | Generating Revenue | ||
1. Seed Round | 22-Jun-2011 | 00000 | 00000 | Completed | Startup |
Affinity Biologicals Executive Team (2)
Name | Title | Board Seat | Contact Info |
---|---|---|---|
Hugh Hoogendoorn | Co-Founder, Director & President | ||
Patricia Hoogendoorn | Co-Founder & Chief Financial Officer |
Affinity Biologicals Signals
Affinity Biologicals Former Investors (1)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Foundation Venture Capital Group | Venture Capital | Minority | 000 0000 | 000000 0 |